With extensive knowledge in complex chemistry, Jane advises clients in life sciences, with a particular focus on small molecule pharmaceuticals. She has a deep understanding of the entire lifecycle of product development and aids her clients in protecting innovations from the initial discovery and testing through all later stage drug development, including protection for specific formulations and platform technologies. Through her extensive network of global contacts, she has strategically helped her clients build commercially valuable worldwide patent portfolios in over 50 countries and regions. Jane is also highly skilled in patent appeal and reexamination in front of the Patent Trial and Appeal Board. Beyond patent practice, she has extensive experience in IP due diligence connected to licensing and financing transactions, patent landscape, infringement and invalidity analyses, product clearance, and general IP strategy.
Jane advises and counsels a diverse range of clients from publicly traded companies, venture-funded start-ups, research institutions, to individual inventors. She has worked on numerous technologies, including a variety of pharmaceutical inventions for treatment of obesity, metabolic syndrome, cancers, idiopathic pulmonary fibrosis, bacterial infections, and liver diseases, as well as liposome delivery technologies. Outside of small molecule pharmaceuticals, Jane also manages portfolios involving next-generation sequencing applications, flowcells and microfluidic devices, polymer materials, medical devices, and aesthetics and personal care products. She also advises foreign internet and media clients on matters related to copyright protection, enforcement and data privacy.
Jane obtained her doctorate in organic chemistry at Pennsylvania State University, where her research concentrated on the design and synthesis of small molecule chiral ligands for transition metals catalyzed asymmetric reactions. Prior to joining Knobbe Martens, she worked as a patent agent in an IP boutique in New Jersey.
Jane joined the firm in 2011 and became a partner in 2018.
Contributor – Biotechnology Blog
PTAB Adopts Phillips Standard for Claim Construction in AIA Proceedings - Knobbe Martens (October 2018)
FDA to Hold Public Hearing on Biosimilar Action Plan - Knobbe Martens (July 2018)
FDA Announces Public Meeting on Regulation of Cultured Meat Products - Knobbe Martens (June 2018)
China Drug Administration Proposes Pharmaceutical Data Protection Guidelines - Knobbe Martens (May 2018)
Supreme Court Will Not Review Pay-For-Delay Case over GSK's Lamictal - Knobbe Martens (November 2016)
Aralez's YOSPRALA Wins FDA Approval - Knobbe Martens (September 2016)
China applying for more patents than ever before as companies push to innovate, protect brand - South China Morning Post (June 2017)
Dai, Q.; Zhang, X. “Development of a New Class of C1-Symmetric Bisphosphine Ligands for Rhodium Catalyzed Asymmetric Hydrogenation.” Tetrahedron 2008, 64, 6943 - 6948.
Dai, Q.; Zhang, X. In Electronic Encyclopedia of Reagents for Organic Synthesis; John Wiley & Sons, 2008; published online.
Dai, Q.; Gao, W.; Liu, D.; Kapes, L. M.; Zhang, X. “Triazole-based monophosphine ligands for palladium catalyzed cross-coupling reactions of aryl chlorides.” J. Org. Chem. 2006, 71, 3928 – 3934.
Dai, Q.; Wang, C.; Zhang, X. “Chiral bisphospholane ligands (Me-Ketalphos): Synthesis of their Rh(I) complexes and applications in asymmetric hydrogenation.” Tetrahedron 2006, 62, 868 – 871.
Dai Q.; Yang, W.; Zhang, X. “Efficient rhodium catalyzed asymmetric hydrogenation for the synthesis of a new class of N-aryl β-amino acid derivatives.” Org. Lett. 2005, 7, 5343 – 5345.
Liu, D.; Gao, W.; Dai, Q.; Zhang, X. “Triazole-based monophosphines for Suzuki-Miyaura coupling and amination reactions of aryl chlorides.” Org. Lett. 2005, 7, 4907 – 4910.
Liu, D.; Dai, Q.; Zhang, X. “A new class of readily available and conformationally rigid phosphino-oxazoline ligands for asymmetric catalysis.” Tetrahedron 2005, 61, 6460 – 6471.
Dai, Q.; Yang, W.; Zhang, X. “Efficient synthesis of protected β-amino acid derivatives via asymmetric hydrogenation," The 230th ACS National Meeting, Washington, D.C., Fall 2005.
Dai, Q.; Liu, D.; Zhang, X. “Synthesis and application of new phosphine-oxazoline ligands,” The 228th ACS National Meeting, Philadelphia, Pennsylvania, Fall 2004.